Trial site
Changzhou No 2 Peoples Hospital
- 19running trials
- 2closed trials
The trials here
What the 21 trials at this site are about, from their registry records.
- Conditions
- Crohn's disease8 trials
- Ulcerative colitis5 trials
- Psoriasis3 trials
- Psoriatic arthritis3 trials
- Multiple myeloma2 trials
- Asthma1 trial
- Atrial fibrillation1 trial
- Coronary artery disease1 trial
- Lung cancer1 trial
- Sjögren's disease1 trial
- Phase
- Phase 313 trials
- Phase 24 trials
- Phase 2/32 trials
- Phase 41 trial
- Status
- Active, not recruiting12 trials
- Recruiting7 trials
- Completed2 trials
- Lead sponsor
- Janssen Research & Development, LLC20 trials
- Xian-Janssen Pharmaceutical Ltd.1 trial
Running trials
Recruiting
A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe Asthma
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Recruiting
Active, not recruiting
Recruiting
A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Active, not recruiting
Active, not recruiting
Recruiting
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
Recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Crohn's disease4 recruiting
- Ulcerative colitis3 recruiting
- Asthma1 recruiting
- Psoriasis1 recruiting
- Psoriatic arthritis1 recruiting
Closed trials
Site data: ClinicalTrials.govUpdated 17 Nov 2026